<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 10, 1999
---------------
BECTON, DICKINSON AND COMPANY
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 001-4802 22-0760120
- --------------------------------------------------------------------------------
(State or other juris- (Commission (IRS Employer Iden-
diction of incorporation) File Number) tification Number)
1 Becton Drive, Franklin Lakes, New Jersey 07417-1880
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (201) 847-6800
--------------
N/A
- --------------------------------------------------------------------------------
(Former name or former addresses if changed since last report.)
<PAGE>
Item 5. OTHER EVENTS
------------
Press release dated August 9, 1999.
Attached hereto as Exhibit 99, which is incorporated
herein by reference, is a copy of the press release.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BECTON, DICKINSON AND COMPANY
(Registrant)
By: /s/ Bridget M. Healy
----------------------------
Bridget M. Healy
Vice President and Secretary
Date: August 10, 1999
- 2 -
<PAGE>
INDEX TO EXHIBITS
-----------------
Exhibit
Number Description of Exhibits
------ -----------------------
99 Press release dated August 9, 1999.
<PAGE>
Exhibit 99
Contacts:
Ronald Jasper
Becton Dickinson and Company
(201) 847-7160
William W. Sims
Clontech Laboratories, Inc.
(650) 424-8222, x1186
Becton, Dickinson and Company Announces
Revised Agreement for Acquisition of Clontech Laboratories, Inc.
Franklin Lakes, NJ--Monday, August 9, 1999--Becton, Dickinson and Company
(NYSE: BDX) announced today that it has entered into a revised agreement to
acquire Clontech Laboratories, Inc., a privately-held company serving the life
sciences market in the areas of gene-based drug discovery technology and
molecular biology research. The revised agreement provides for the acquisition
of Clontech by BD in exchange for $200 million in cash. Under the previously
announced agreement signed in April 1999, BD was to acquire Clontech in an
approximately $200 million stock-for-stock exchange. The companies expect to
complete the transaction by August 31, 1999, following receipt of required
consents and approvals.
Becton Dickinson and Company manufactures and sells a broad range of
medical supplies and devices and diagnostic systems for use by health care
professionals, medical research institutions, industry and the general public.
###
